Table 3. Multivariate analysis of prognostic factors for NPC patients.

Outcomes	Variable	p	HR	95%CI for HR
OS
	Sex (male vs. female)	0.437	0.703	0.289–1.710
	Age (>44 vs. ≤44)	0.509	0.745	0.311–1.785
	Clinical stage (IV vs. II&III)	0.276	1.688	0.658–4.335
	T stage (T3-4 vs. T1-2)	0.19	0.504	0.181–1.406
	N stage (N2-3 vs. N0-1)	0.087	2.842	0.858–9.414
	M stage (M1 vs. M0)	0.773	0.819	0.211–3.182
	PTOV1 expression (high vs. low)	0.03	3.453	1.13–10.545
PFS
	Sex (male vs. female)	0.542	0.824	0.441–1.537
	Age (>44 vs. ≤44)	0.045	0.522	0.276–0.986
	Clinical stage (IV vs. II&III)	0.191	0.634	0.320–1.254
	T stage (T3-4 vs. T1-2)	0.244	1.785	0.673–4.731
	N stage (N2-3 vs. N0-1)	0.223	0.635	0.305–1.319
	M stage (M1 vs. M0)	0.002	8.18	2.209–30.282
	PTOV1 expression (high vs. low)	<0.001	4.210	1.900–9.327

Abbreviations: CI = confident interval; HR = hazard ratio; OS = overall survival; PFS = progression-free survival